MCL Literature Feed

IGH/IGK gene rearrangement analysis improves diagnostic accuracy for B-cell lymphomas, with co-occurring IGH and IGK rearrangements being a characteristic feature of mantle cell lymphoma.

The m6A writer METTL3 promotes MCL progression by degrading Ambra1 mRNA via the reader YTHDF2, identifying a novel, potentially targetable therapeutic axis for mantle cell lymphoma.

This meta-analysis in TP53-mutated MCL supports targeted therapy frontline and CAR-T or transplant in relapse, but confirms poor long-term survival, highlighting the need for novel approaches.

This MZL case identifies BTK C481S and PLCG2 D334H co-mutations driving zanubrutinib resistance, a mechanism highly relevant to BTKi failure and subsequent treatment strategies in relapsed MCL.

This study identifies predictors of outcome for covalent BTKi therapy in relapsed/refractory TP53-mutant MCL, helping to risk-stratify patients and guide subsequent treatment decisions.

A targeted NGS panel characterized the mutational landscape of Korean lymphomas, including MCL, demonstrating its utility for identifying clinically relevant mutations like TP53 in diverse subtypes.

This conference report identifies key controversies in B-cell lymphoma management, initiating a formal process to develop expert consensus guidelines for navigating increasingly complex treatment selection and sequencing decisions.

A rare composite MCL/LPL case reveals a cryptic IGK::CCND1 fusion driving the MCL, highlighting the diagnostic utility of molecular testing for atypical CCND1 rearrangements.

This review summarizes current MCL risk stratification (MIPI, TP53), highlights emerging genomic biomarkers, and emphasizes MRD monitoring as a key dynamic tool for personalizing therapy, especially for high-risk patients.

This preclinical study identifies CEACAM1 as a novel activator of B-cell receptor signaling by recruiting SYK, revealing a new potential therapeutic target and mechanism of resistance to BCR inhibitors.

The novel circular RNA-based biomarker, circSCORE, demonstrates prognostic value in relapsed/refractory MCL, offering a new tool for risk stratification in this high-risk patient population.

A novel single-cell method integrating biophysical properties with transcriptomics identifies distinct MCL subpopulations, suggesting cell mechanics could be a new biomarker for tumor heterogeneity and therapeutic resistance.

A rare B-ALL subtype with a MEF2D::BCL9 fusion can mimic blastoid MCL by co-expressing CD5 and SOX11, highlighting a critical diagnostic pitfall requiring molecular confirmation.

This review provides a practical guide for differentiating aggressive B-cell lymphomas, including mantle cell lymphoma, emphasizing the integration of morphology, immunohistochemistry, and molecular testing for accurate diagnosis and classification.

High p62 expression predicts poor survival in MCL by upregulating CCND1 transcription via Nrf2, identifying p62 as a novel prognostic biomarker and potential non-BTK/BCL2 therapeutic target.

A novel single-cell genomic research model tracks MCL clonal evolution, providing a high-resolution tool to dissect mechanisms of therapeutic resistance and identify potential new targets.

NGS-detected TP53 mutations are a major clinical risk factor, enabling precise patient stratification to guide initial therapy selection and identify candidates for novel agents.

Optical genome mapping reveals diverse cryptic CCND1/2 rearrangements in ~10% of MCLs lacking the classic t(11;14), improving diagnosis and identifying high genomic complexity associated with poor outcomes.

Optical genome mapping detects additional clinically significant genomic aberrations in 8% of mantle cell lymphoma cases compared to standard cytogenetics, potentially improving risk stratification.

In young, fit MCL patients undergoing frontline autotransplant, large clonal hematopoiesis clones (VAF ≥10%) at baseline are a novel biomarker for worse progression-free and overall survival.

The novel TBL1X inhibitor tegavivint induces DNA damage and synergizes with PARP inhibitors in preclinical MCL models, establishing TBL1X as a new therapeutic target for genomic instability.

This case report describes a rare CCND1-negative mantle cell lymphoma presenting atypically as leukemia, highlighting the need to consider this diagnosis despite the absence of the classic translocation.

This case series reports an incidental MCL diagnosis from a cervical lymph node during thyroid cancer surgery, underscoring the need for thorough pathological evaluation in atypical presentations.

This review clarifies updated WHO-5 diagnostic criteria for high-grade B-cell lymphoma, emphasizing the crucial pathologic and genetic distinction from blastoid mantle cell lymphoma to ensure correct patient management.

This case of clonally-related composite DLBCL and CD5-negative MCL highlights a rare diagnostic challenge, emphasizing the need for comprehensive IHC panels to avoid misdiagnosing transformed lymphoma.

Genomic analysis of a single MCL patient identified specific mechanisms of resistance to PD-L1 blockade, providing crucial insights into why checkpoint inhibitors are often ineffective in this lymphoma.

Integrated genomic and transcriptomic profiling identifies novel molecular subsets of MCL that predict patient outcomes, paving the way for risk-stratified therapy.

A Mendelian randomization study suggests a causal link between higher abundance of the gut bacterium Holdemania filiformis and a significantly reduced risk of developing mantle cell lymphoma.

This review summarizes the genomic, molecular, and pathological variations in MCL, highlighting how this biological heterogeneity impacts risk stratification, prognosis, and the development of personalized therapies.

A cross-validated, lymphoma-tailored NGS panel demonstrates high accuracy, providing a framework for implementing standardized genomic testing for prognostication in routine MCL clinical practice.